A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (NCT05805501)
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- UC Irvine Medical Center — Orange, California
- Emory University — Atlanta, Georgia
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- UT Southwestern Medical Center — Dallas, Texas
- Sunshine Coast University Hospital — Birtinya, Queensland
- Peking University First Hospital — Beijing,
- Beijing Cancer Hospital — Beijing,
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School — Nanjing,
- Tianjin Cancer Hospital — Tianjin,
- Institut Sainte Catherine — Avignon,
- CHU Besançon - Hôpital Jean Minjoz — Besançon,
- CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre — Bordeaux,
- Centre Francois Baclesse — Caen,
- Centre Leon Berard — Lyon,
- Institut Gustave Roussy — Villejuif,
- Universitätsklinikum "Carl Gustav Carus" — Dresden,
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II — Hamburg,
- Medizinische Hochschule Hannover — Hanover,
- Klinikum rechts der Isar der TU München — München,
- Studienpraxis Urologie — Nürtingen,
- Universitätsklinikum Ulm — Ulm,
- Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny — Brzozów,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.